# Peter Rossing

Organization · id `cardio:org-peter-rossing` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Peter+Rossing>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class other. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Peter Rossing
- Sponsor class: OTHER

## Connected pages

- Sponsors: Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria (`cardio:ct-nct02040441`)
- Sponsors: Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study (`cardio:ct-nct06906081`)
- Sponsors: A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease (`cardio:ct-nct07239570`)

## Provenance

Content hash: 501cc1cd63947379162e270dba9bff20999c104df34643457b3ba73df450596e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
